New drug ALN-4915 tested for safety in healthy people
NCT ID NCT07535606
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 4 times
Summary
This early-phase trial is testing the safety and tolerability of a new drug called ALN-4915 in 44 healthy adults. Participants receive a single injection of either the drug or a placebo, and researchers monitor for side effects and how the drug moves through the body. Since this is a phase 1 study in healthy volunteers, there is no direct treatment benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ALN-4915
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Trial Site
RECRUITINGLondon, NW10 7EW, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults